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The Eph receptor tyrosine kinases and their ligands,
the ephrins, regulate numerous biological processes
in developing and adult tissues and have been impli-
cated in cancer progression and in pathological forms
of angiogenesis. We report the crystal structure of the
EphB4 receptor in complex with a highly specific
antagonistic peptide at a resolution of 1.65 A˚. The
peptide is situated in a hydrophobic cleft of EphB4
corresponding to the cleft in EphB2 occupied by the
ephrin-B2 G-H loop, consistent with its antagonistic
properties. Structural analysis identifies several resi-
dues within the EphB4 binding cleft that likely deter-
mine the ligand specificity of this receptor, while
isothermal titration calorimetry experiments with trun-
cated forms of the peptide define the amino acid resi-
dues of the peptide that are critical for receptor bind-
ing. These studies reveal structural features that will
aid drug discovery initiatives to develop EphB4 antag-
onists for therapeutic applications.
Introduction
The erythropoietin-producing hepatocellular carcinoma
(Eph) receptors and their ligands, the ephrins, play crit-
ical roles in angiogenesis during embryonic develop-
ment as well as in adult tissues (Gale and Yancopoulos,
1999; Cheng et al., 2002; Kullander and Klein, 2002;
Brantley-Sieders and Chen, 2004). The Eph family of re-
ceptor tyrosine kinases also regulates many other bio-
logical processes, including tissue patterning, axonal
guidance, and, as more recently discovered, tumorigen-
esis (Carmeliet and Collen, 1999; Ferrara, 1999; Wilkin-
son, 2000; Pasquale, 2005). Both the Eph receptor and
the ephrin are membrane bound, and therefore require
*Correspondence: pkuhn@scripps.educell-cell contact to signal a cellular response. The inter-
action between Eph receptors and ephrins on adjacent
cell surfaces results in multimerization and clustering
of the Eph-ephrin complexes, leading to forward signal-
ing in the Eph-expressing cell and reverse signaling in
the ephrin-expressing cell. EphB4 belongs to the Eph
family of receptor tyrosine kinases, which is divided
into two subclasses, A and B, based on binding prefer-
ences and sequence conservation (Gale et al., 1996).
In general, EphA receptors (EphA1–EphA10) bind to gly-
cosyl phosphatidyl inositol (GPI)-anchored ephrin-A
ligands (ephrin-A1–ephrin-A6), while EphB receptors
(EphB1–EphB6) interact with transmembrane ephrin-B
ligands (ephrin-B1–ephrin-B3) (Eph Nomenclature Com-
mittee, 1997). While interactions between the Eph recep-
tors and ephrin ligands of the same subclass are quite
promiscuous, interactions between subclasses are
rare. A few cross-subclass exceptions include the
EphA4-ephrin-B2/B3 interactions (Takemoto et al.,
2002), and the EphB2-ephrinA5 interaction, which has
been characterized structurally (Himanen et al., 2004).
EphB4 is unique within the Eph family in that it selec-
tively binds ephrin-B2, while demonstrating only weak
binding for both ephrin-B1 and ephrin-B3.
Eph receptors have a modular structure, consisting of
an N-terminal ephrin binding domain adjacent to a cyste-
ine-rich domain and two fibronectin type III repeats in
the extracellular region. The intracellular region consists
of a juxtamembrane domain, a conserved tyrosine ki-
nase domain, a C-terminal sterile a-domain, and a PDZ
binding motif. The N-terminal 180 amino acid globular
domain is sufficient for high-affinity ligand binding
(Himanen et al., 2001). Previously described crystal
structures of the EphB2 receptor in the apo and ephrin
bound forms have identified the binding interfaces be-
tween receptor and ligand, revealing a high-affinity bind-
ing interface that mediates dimerization of Eph and
ephrin molecules, and a distinct lower-affinity binding
interface mediating tetramerization of two Eph-ephrin
dimers of the same subclass (Himanen et al., 2001,
2004). The structures of EphB2 in complex with
ephrin-B2 or ephrin-A5 show that the ephrin G-H loop
is inserted into a hydrophobic cleft of EphB2 at the high-
affinity dimerization interface in all structures thus far
reported. In addition to the natural ephrin ligands, pep-
tides and peptide mimetics that bind with high affinity
to Eph receptors may represent useful probes to char-
acterize the range of interactions that can be accom-
modated by the ephrin binding interfaces of the Eph
receptors.
During vascular development, EphB4 is predomi-
nantly expressed by venous endothelial cells, while its
membrane-associated ligand, ephrin-B2, is primarily ex-
pressed by arterial endothelial cells (Wang et al., 1998;
Adams et al., 1999). Deletion of either receptor or ligand
during embryogenesis results in embryonic lethality due
to defects in vessel remodeling in both the arterial and
venous vasculature. Stimulation of ephrin-B2 reverse
signaling by EphB4 promotes endothelial cell prolifera-
tion, survival, and migration in vitro (Fuller et al., 2003;
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322Hamada et al., 2003; Noren et al., 2004) and increases tu-
mor growth in vivo in a mouse breast cancer xenograft
model by stimulating angiogenesis (Noren et al., 2004;
Koolpe et al., 2005). In fact, EphB4 expression is upregu-
lated in colon, prostate, lung, gastric, and breast can-
cers compared to normal tissue, consistent with a role
for this receptor in cancer development or progression
(Dodelet and Pasquale, 2000; Stephenson et al., 2001;
Noren et al., 2004; Xia et al., 2005). EphB4 overexpres-
sion in cancer cells would be predicted to promote tu-
morigenesis and angiogenesis by stimulating reverse
signaling through ephrin-B2. EphB4 forward signaling,
on the other hand, has been shown to inhibit cellular pro-
liferation, at least in vitro (Noren et al., 2004). However,
the overall role of ephrin-B2-EphB4 signaling in patho-
logic angiogenesis and tumor growth remains poorly
understood.
Several 12 amino acid peptides that selectively bind to
individual Eph receptors were recently identified by
phage display (Koolpe et al., 2002; Murai et al., 2003;
Koolpe et al., 2005). A number of EphB4 binding pep-
tides could be aligned with each other and the 15
amino-acid segment corresponding to the ephrin-B2
G-H loop (Koolpe et al., 2005). The TNYL EphB4 binding
peptide was modified based on this alignment to include
a carboxy terminal RAW sequence. The resulting TNYL-
RAW (TNYLFSPNGPIARAW) peptide is a potent antago-
nist of ephrin-B2 binding to EphB4, with an IC50 value of
w15 nM for the murine receptor, which is comparable to
the IC50 ofw10 nM measured for ephrin-B2 (Table 1). In-
terestingly, the TNYL peptide (which lacks the carboxy-
terminal RAW sequence) is 10,000-fold less potent than
TNYL-RAW (IC50 of w150 mM). We present here the
structural and thermodynamic characterization of the
EphB4-TNYL-RAW interaction. The peptide is situated
in the same hydrophobic cleft occupied by the ephrin-B2
G-H loop, assuming a position distinct from this loop
and preventing ligand binding interactions at two high-
affinity dimerization interfaces. Although the peptide
binds independently from the ephrin ligand, the interac-
tions within the binding cleft are remarkably similar to
previous complex structures, providing a stable network
of interactions for binding. Furthermore, structural anal-
ysis reveals the molecular determinants for the directed
specificity of this antagonist for the EphB4 receptor, al-
lowing the first insights into modulating pathways re-
sulting in tumorigenesis and angiogenesis that rely on
EphB4-ephrin-B2 signaling.
Results
Structural Topology of the EphB4 Receptor
The crystal structure of the human EphB4 ligand binding
domain in complex with the antagonistic TNYL-RAW
peptide was refined to a 1.65 A˚ resolution. The structure
of the EphB4 receptor is similar to the EphB2 receptor
(Himanen et al., 1998), consisting of a jellyroll folding to-
pology composed of 13 antiparallel b sheets (Figure 1)
arranged as a compact b sandwich, with the concave
sheet comprised of strands C, F, F0, L, H, and I, and
the convex sheet comprised of strands D, E, A, M, G,
K, and J (nomenclature according to Himanen et al.,
1998). Loops with a varying number of amino acids link
each of these b sheets. The corresponding loops inEphB2 have been shown to play essential roles in recep-
tor-ligand dimerization (D-E, E-F, G-H, J-K) and tetrame-
rization (H-I). Two conserved disulfide bridges that are
strictly conserved across Eph receptor subclasses sta-
bilize the G-H loop and the E-F/L-M loops at the top of
the b sandwich. The structure of the globular domain
of EphB4 is similar to the apo, ephrin-B2, and ephrin-A5
bound EphB2 structures determined previously (Fig-
ure 2), with rmsds of 1.05, 1.08, and 0.94 A˚ over equiva-
lent Ca positions (Himanen et al., 1998, 2001, 2004).
The ephrin binding domain of human EphB4 shares
45% sequence identity with that of human EphB2. Like
the EphB2 crystals, the crystals of EphB4 in complex
with the TNYL-RAW peptide contain one molecule in
the asymmetric unit. Unlike the apo EphB2 structure,
however, the D-E and J-K loops are well ordered in
EphB4 and form the peptide binding channel (Figure 2).
Table 1. IC50 Values of Peptides and Ephrin-B2 for Inhibition of
Mouse Ephrin-B2 Alkaline Phosphatase Binding to Immobilized
Mouse EphB4 Ectodomain Fc Fusion Protein With ELISA
Binding Assays
Inhibitor IC50
Ephrin-B2 Fc 9 nM
Human ephrin-B2 monomer 10 nM
TNYLFSPNGPIARAW (TNYL-RAW)a 15 nM
–NYLFSPNGPIARAW (NYLF-RAW) 40 nM
––YLFSPNGPIARAW (YLFS-RAW) 40 nM
–––LFSPNGPIARAW (LFSP-RAW) >10 mM
TNYLFSPNGPIA (TNYL) 150 mM
TNYLFSPNGPIAGSGSK-biotin (TNYL-biotin) 50 mM
a Ephrin-B2 G-H loop: KFQEFSPNLWGLEFQK.
Figure 1. The Ephrin Binding Domain of the EphB4 Receptor in
Complex with an Antagonistic Peptide, TNYL-RAW
The ephrin binding domain (a helices in green, b-sheets in red, loops
in blue, and peptide in magenta) consists of a jellyroll folding topol-
ogy with 13 antiparallel B-sheets connected by loops of varying
lengths. Peptide binding orders the D-E and J-K loops, which cannot
be visualized in the apo structure of the related EphB2 receptor.
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the corresponding loops of the previously described
EphB2-ephrin complex structures. Most notably, the
J-K loop is significantly shifted in order to avoid steric in-
terference with the peptide. In fact, this loop is displaced
by over 20 A˚ and 17 A˚ from the furthest Ca positions in
the structure of EphB2 in complex with ephrin-B2 or
ephrin-A5, respectively. The D-E loop is also shifted
due to the presence of the antagonist peptide, deviating
2.3 A˚ and 3.2 A˚ from the structures of EphB2 in complex
with ephrin-B2 and ephrin-A5, respectively. Less signif-
icant changes occur at adjacent loops involved in dimer-
ization, due to the new position of the J-K loop, including
the disulfide-stabilized G-H loop and the C-D loop,
which contains a unique two amino acid insert not found
in any other Eph receptors. This insert does not appear
to play a role in peptide or ephrin binding and, therefore,
presumably does not contribute to the ligand selectivity
of EphB4.
EphB4-Ephrin-B2 Interaction
Because the overall topology of the EphB4 binding cleft
is similar to that of EphB2, we were able to superimpose
the structure of EphB4 on the EphB2-ephrin-B2 struc-
ture described previously (Himanen et al., 2001; Fig-
ure 3). The ephrin-B2 G-H loop forms contacts similar
to those described in the structure of the EphB2-
ephrin-B2 complex. This high-affinity binding interface
is highly hydrophobic, and includes residues Phe-120,
Pro-122, Leu-124, Trp-125, and Leu-127 of ephrin-B2.
The G-H loop of ephrin-B2 is buttressed by the G-H
and J-K loops of EphB4, and should form similar main
chain hydrogen bonds and numerous van der Waals in-
teractions with EphB4, as previously described in the
complex with EphB2 (Himanen et al., 2001, 2004). In ad-
dition, the conserved Cys-61-Cys-184 disulfide bridge
of EphB4 is stabilized by Pro-122 from the conserved
Figure 2. Superposition of the EphB4 Receptor on the EphB2 Re-
ceptor from the EphB2-Ephrin-B2 Structure
The EphB4 receptor is shown in red and the EphB2 (Himanen et al.,
2001, PDB code: 1KGY) is shown in blue. The structures are super-
imposed with an overall rmsd of 1.08 A˚ between equivalent Ca posi-
tions. The J-K loop is displaced by as much as 20 A˚ in EphB4 com-
pared to EphB2.FSPN segment of the ephrin-B2 G-H loop. Due to the im-
portance of Pro-122 in the positioning of the EphB4 G-H
loop, it is expected that this residue would assume a po-
sition similar to that described in the complex with
EphB2. It is also likely that the J-K loop of EphB4 would
shift toward ephrin-B2 in order to maximize the binding
potential between receptor and ligand, as observed in
the EphB2-ephrin crystal structures. Indeed, the Eph re-
ceptor J-K loop displays remarkable flexibility and is
present in a different conformation in EphB2 bound to
ephrin-B2 or to ephrin-A5. In addition, the J-K loop in
the apo structure of EphB2 could not be visualized prob-
ably because it is disordered in the absence of a bound
ligand (Himanen et al., 1998, 2001, 2004).
A second, lower-affinity binding interface between
EphB2 and ephrin-B2 has been structurally character-
ized (Figure 3). This interface, which has been implicated
in tetramerization, is absent in the EphB2-ephrinA5
complex, suggesting that it confers subclass binding
specificity (Himanen et al., 2001, 2004). The interface is
framed by the H-I subclass-specificity loop. In EphB4,
this loop is similar to the EphB2 H-I loop, with a maxi-
mum displacement of 2.5 A˚ at conserved residue
Thr-27 of EphB4. Like the EphB2-ephrin-B2 low-affinity
interface, the EphB4-ephrin-B2 interface is dominated
by hydrophobic interactions and few weak polar con-
tacts between the receptor H-I loop and the A-A0
b strands of the ephrin. Hydrophobic interactions similar
to those observed in the EphB2-ephrin-B2 complex can
also be modeled between the F-G and K-L loops of
EphB4 and the C-D loop of ephrin-B2.
TNYL-RAW Peptide Binding
The TNYL-RAW peptide could be readily modeled into
the electron density after initial rounds of refinement with
unbiased electron density from simulated annealing omit
Figure 3. Model of the EphB4-Ephrin-B2 Complex
The EphB4 (blue)-ephrin-B2 (green) complex is predicted to form
interactions similar to those previously described in the EphB2-
ephrin-B2 complex. Although several interactions are likely absent
in the EphB4-ephrin-B2 complex compared to the EphB2-ephrin-B2
complex, the tetramer is likely to form at high EphB4 and ephrin-B2
concentrations.
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324Figure 4. Stereoview of Sigma-A Weighted 2jFobsj 2 jFcalcj Electron Density at 1.65 A˚ Resolution, Contoured at 1s for the Antagonistic TNYL-
RAW Peptide
The peptide was placed into the density after an initial round of structure refinement. The N-terminal threonine lacks clear electron density and is
therefore absent from the structure.maps and jFobsj2 j Fcalcj,Vcalc maps (Figure 4). The pep-
tide is inserted into the same cleft occupied by ephrin-
B2, along the hydrophobic upper convex portion of the
EphB4 receptor, which is situated on top of a b-sheet
‘‘floor’’ formed by b strands D and E. In addition, loops
D-E, E-F, G-H, and J-K effectively buttress the peptide
in the cavity, forming numerous van der Waals interac-
tions and main chain hydrogen bonds that stabilize
binding. Although the TNYL-RAW peptide shares the
FSPN sequence motif with the G-H loop of ephrin-B2
(Koolpe et al., 2005), surprisingly it assumes a distinct
conformation as compared with the ephrin-B2 G-H
loop bound to EphB2 (Himanen et al., 2001; Figure 5).
The peptide has little secondary structure at the N termi-
nus, but forms a pseudohelix at its C-terminal end. A gly-
cine-proline motif in the middle of the peptide induces
a sharp 90º turn that angles the peptide into the upper
edge of the binding cleft adjacent to the EphB4 G-H
loop, where the high affinity-conferring RAW sequence
binds.
Figure 5. Superposition of the TNYL-RAW Peptide on the EphB4-
Ephrin-B2 Model
The ligand G-H loop extends into the hydrophobic binding cleft
of the EphB4 receptor such that the TNYL-RAW peptide (orange) and
the ephrin-B2 G-H loop (red) compete for the same binding site.
Position of the peptide is distinct from the ephrin-B2 G-H loop.The N-terminal residue of the peptide Thr-P1 could
not be modeled into the electron density map, and
therefore is not depicted in the final model of the com-
plex. The adjacent Asn-P2 is located along the plane
of b strand D of EphB4, between the D-E and J-K loops,
and forms few interactions with the receptor (Figure 6A).
The position of Asn-P2 suggests that the N-terminal Thr-
P1 may be disordered because it does not bind to
EphB4, likely explaining its absence in the electron den-
sity map. Tyr-P3 is positioned on top of b-sheet D, form-
ing a pseudo-sandwich between the D-E loop of the
EphB4 receptor and the N-terminal end of the peptide.
Similar interactions are observed between Trp-125 of
ephrin-B2 and the EphB2 D-E loop. These interactions
likely play a key role in ordering this region of the bound
ephrin (Himanen et al., 2001, 2004).
The G-H loop of ephrin-B2 contains a conserved
FSPN sequence, which plays an essential role in recep-
tor binding, and is the only sequence within the G-H loop
that is also present in the TNYL-RAW peptide. Substan-
tial hydrophobic interactions between this sequence
and the G-H loop of the EphB2 receptor essentially
lock ephrin-B2 into the binding cleft of the receptor (Hi-
manen et al., 2001). In the structure of the peptide in
complex with EphB4, the corresponding Phe-P5 of the
peptide is completely buried by the J-K loop of the re-
ceptor and by residues of the peptide, including Ile-
P11 and Trp-P15. This residue is situated more than
8 A˚ away from the equivalent phenylalanine residue in
the ephrin-B2 G-H loop, and the N- to C-terminal orien-
tation of the FSPN sequence in the ephrin and the pep-
tide are pointed in opposite directions. Furthermore, un-
like the SPN sequence of ephrin-B2 in complex with
EphB2, the SPN sequence of the peptide is not buried
by the hydrophobic G-H loop of EphB4, but instead is
positioned along the solvent-exposed surface of the re-
ceptor. The side chain of Ser-P6 forms a hydrogen bond
with the main chain nitrogen of Asn-P8, which, together
with the intervening Pro-P7, contributes to a sharp turn
in the middle of the peptide. This turn positions Ile-P11
to interact with the conserved disulfide bridge in the
E-F and L-M loops of EphB4 (Cys-61-Cys-184). Ile-P11
resides in the equivalent position as the conserved
Pro-122 in ephrin-B2 (Pro-125 in ephrin-A5), which inter-
acts with the corresponding disulfide bridge (Cys-60-
Cys-192) in EphB2. The side chain of Ile-P11 forms
a frame similar to the ephrin-B2 Pro-122 CD, CG, and
EphB4 Receptor/EphrinB2 Antagonist Complex Structure
325Figure 6. Detailed View of Critical EphB4-
TNYL-RAW van der Waals Interactions and
Schematic LIGPLOT Diagram of EphB4-
TNYL-RAW Interactions
(A) All interactions are less than 4 A˚ and indi-
cated by dashed green lines. The peptide
(yellow) is depicted with all bonds shown,
while receptor residues (cyan) are drawn
schematically. Water and sulfates have
been removed for clarity.
(B) The peptide (purple) is depicted with all
bonds shown, while receptor residues (red
spoked arcs) involved in hydrophobic inter-
actions with the peptide are drawn schemat-
ically. Peptide atoms involved in hydrophobic
contacts have spokes coming out of the indi-
vidual atoms. Receptor residues (orange) in-
volved in hydrogen bond interactions with
the peptide are depicted with all bonds. Hy-
drogen bonds are shown as dashed green
lines. Water and sulfates have been removed
for clarity.CB positions, thus providing a hydrophobic backbone
that stabilizes the position of the functionally important
disulfide bridge in EphB4.
Alignment of a number of the EphB4 binding peptides
that were identified by phage display revealed a con-
served glycine-proline motif corresponding to a trypto-
phan located at the tip of the ephrin-B2 G-H loop.
Although proline and tryptophan are not structurally
similar, the G-P residues in the peptides were predicted
to mimic the turn of the middle of the ephrin G-H loop
(Koolpe et al., 2005). Surprisingly, the bend induced by
the G-P motif is instead most similar to the turn presentat the beginning of the ephrin-B2 G-H loop and formed
by residues Phe-117, Gln-118, and Glu-119, which angle
the ephrin G-H loop into the hydrophobic cleft of the Eph
receptor. The G-P turn in the TNYL-RAW peptide posi-
tions the RAW sequence into the upper edge of
the EphB4 binding cleft, where Trp-P15 is effectively
stabilized between the J-K and G-H loops of the recep-
tor. Trp-P15 forms a main chain hydrogen bond with
Ser-99 and hydrophobic interactions with Leu-95,
Leu-100, Pro-101, Lys-149, and Phe-P5. These inter-
actions are similar to those formed by Phe-120 in the
ephrin-B2 FSPN motif. Unlike Phe-120 of ephrin-B2,
Structure
326Table 2. Binding of Peptides and Human Ephrin-B2 to Human EphB4 Ephrin Binding Domain
Ligand Kd (nM)
a DG (kcal mol21) DHobs (kcal mol
21) TDS (kcal mol21)
TNYL-RAW 71 6 14 29.8 6 0.1 214.7 6 0.2 24.9 6 0.2
NYLF-RAW 65 6 7 29.8 6 0.1 215.5 6 0.1 25.7 6 0.1
YLFS-RAW 80 6 36 29.7 6 0.2 213.8 6 0.5 24.1 6 0.4
LFSP-RAW 3500 6 680 27.4 6 0.1 25.3 6 0.5 2.1 6 0.4
TNYL R140,000 ND 29.6 6 0.3 ND
Ephrin-B2 40 6 20 210.2 6 0.3 3.3 6 0.1 13.4 6 0.4
Experiments were performed at 25ºC in 50 mM Tris (pH 7.8), 150 mM NaCl, and 1 mM CaCl2. All values (except for TNYL) represent the average of
at least two experiments. ND, not determined.
a The Kd value for the TNYL peptide is a lower limit assuming a stoichiometry of 1 and at least 70% saturation of binding at a final peptide con-
centration of 300 mM.however, Trp-P15 is buried within the hydrophobic bind-
ing cleft, maximizing its interactions with the receptor.
Arg-P13, which is also part of the peptide sequence im-
portant for high-affinity binding, forms a hydrogen bond
with the side chain of Glu-96 of the receptor, and also
aids in structuring the C-terminal end of the peptide by
forming a side chain to main chain hydrogen bond with
the solvent-exposed Asn-P8. Together, Arg-P13 and
Trp-P15 could disrupt several hydrogen bonds in the
high-affinity dimerization interface between EphB4 and
the ephrin-B2 ligand, consistent with the antagonistic
properties of the TNYL-RAW peptide. Overall, the net-
work of interactions between EphB4 and the high affin-
ity-conferring RAW sequence is highly stable (Figure 6B)
and similar to the interactions of the conserved FSPN se-
quence ofephrin-B2. Taken together, these data suggest
that the TNYL-RAW peptide can inhibit ephrin binding
to the high-affinity dimerization interface of the EphB4
ephrin binding domain by steric hindrance. These data
reveal similarities, but also important differences in the
structures of the related EphB2 and EphB4 receptors.
A second region of the dimerization interface has been
characterized adjacent to the high-affinity dimerization
interface that provides significant structural integrity
for complex formation, with numerous hydrogen bonds
formed between receptor and ephrin from backbone-
backbone, backbone-side chain, and side chain-side
chain contacts (Himanen et al., 2001). Several of these
contacts can also be mapped onto a model of the
EphB4-ephrin-B2 complex, including interactions be-
tween Asp-110 (L) and Thr-27 (R), and Lys-112 (L) and
Ser-46 (R). The residues in this second interface of
EphB4 would remain accessible to ephrin-B2 in the pres-
ence of the bound TNYL-RAW peptide. However, the
protruding Arg-P13 and Asn-P8 of the peptide would ste-
rically interfere with the positioning of b strand G of eph-
rin-B2. Arg-P13 in particular extends away from the body
of the peptide into the space that would be occupied by
b strand G of ephrin-B2. Therefore, the presence of the
bound peptide would likely reposition the ephrin such
that weak hydrogen bonds would dominate this affinity
interface, making the interaction much weaker. In addi-
tion, the FSPN residues of the peptide would sterically
clash with several residues at the tip of the low-affinity
EphB4-ephrin-B2 interface, including residues Lys-116,
Phe-117, and Gln-118 of the ephrin ligand.
Thermodynamic Characterization
To experimentally verify the molecular determinants for
the high-affinity binding of the peptide predicted basedon the crystal structure, a thermodynamic characteriza-
tion of TNYL-RAW and truncated forms of this peptide
was performed with isothermal titration calorimetry
(ITC). The binding of TNYL-RAW to the human EphB4
ephrin binding domain (amino acids 17–196) at 25ºC
yields a Kd of 70 nM and a DHobs of 214.7 kcal mol
21
(Table 2). As an internal control, the interaction between
EphB4 (17–196) and the Eph binding domain of human
ephrin-B2 (amino acids 25–187) yielded a Kd of 40 nM
and a DHobs of +3.3 kcal mol
21. This is slightly lower
than the affinity reported for the interaction between
the entire mouse EphB4 extracellular domain and mouse
or human ephrin-B2 (Table 1). The difference may be ex-
plained by the existence of a third low-affinity Eph-ephrin
interface located outside the ephrin binding domain
(Smith et al., 2004).
The structural information suggests that two contact
areas between EphB4 and the peptide are particularly
critical for their interaction. One involves the N-terminal
Tyr-P3 (TNYL), and the other the C-terminal Arg-P13 and
Trp-P15 (RAW). To verify whether these residues are in-
deed critical for high-affinity binding of the TNYL-RAW
peptide to EphB4, the Kd values for binding of peptides
with N- and C-terminal truncations to human EphB4(17–
196) were measured in ITC experiments (Table 2). Dele-
tion of the N-terminal Thr-P1 and Asn-P2 of the peptide
produced negligible changes in affinity (Kd = 65–80 nM)
andDHobs. However, deletion of Tyr-P3 caused a 40-fold
reduction in affinity (Kd = 3.5 mM), indicating that the ty-
rosine is the first residue from the N terminus of the pep-
tide that is required for high-affinity binding. The RAW
sequence is predicted to play an essential role in pep-
tide binding due to its extensive interactions with
EphB4 residues in the EphB4-peptide complex struc-
ture. Truncation of this sequence indeed resulted in
very weak binding (Kd > 140 mM), in agreement with pre-
vious results (Koolpe et al., 2005), indicating that this
region of the peptide provides critical binding determi-
nants. Trp-P15 in particular is highly stabilized by both
polar and hydrophobic interactions with the same region
of EphB4 that is modeled to interact with the conserved
FSPN sequence of ephrin-B2.
Competition studies performed with an ELISA to mea-
sure the ability of truncated forms of the TNYL-RAW
peptide to antagonize murine ephrin-B2 binding to mu-
rine EphB4 also support the ITC results with the human
proteins. Thr-P1 and Asn-P2 do not affect the ability of
TNYL-RAW to inhibit ephrin-B2 binding to EphB4
(Table 1). In contrast, Tyr-P3 was required for efficient
antagonistic properties. The IC50 for inhibition of
EphB4 Receptor/EphrinB2 Antagonist Complex Structure
327ephrin-B2 binding to the TNYL-RAW and YL-RAW
(YLFSPNGPIARAW) peptide is approximately 40 nM,
and that for L-RAW (LFSPNGPIARAW) is approximately
15 mM (Table 1).
Discussion
We have elucidated the high-resolution three-dimen-
sional structure of the ephrin binding domain of the
EphB4 receptor in complex with the TNYL-RAW pep-
tide, which targets the high-affinity ephrin-B2 binding in-
terface. The structure provides a molecular explanation
for the remarkably high binding affinity of the peptide.
Furthermore, it predicts that the TNYL-RAW peptide
should be a particularly effective antagonist by interfer-
ing with ephrin-B2 binding not only to the high-affinity
binding cleft of EphB4, but also to the adjacent regions
of the dimerization interface. These regions are critical
for EphB4-ephrin-B2 signaling.
EphB4 is the sole member of the Eph receptor family
that interacts preferentially with only one ephrin ligand,
ephrin-B2, whereas it is only weakly activated by eph-
rin-B1 and ephrin-B3, the other two ephrins of the B sub-
class. EphB2, on the other hand, is activated by multiple
ephrins, including one from the A subclass (Himanen
et al., 2004). The overall structure of the EphB4 ephrin
binding domain is similar to that previously reported
for EphB2 (Himanen et al., 1998, 2001, 2004). Further-
more, the overall topology of the high-affinity dimeriza-
tion interface is remarkably similar between the EphB2
and EphB4 structures, considering that only 42% of
the residues in the EphB4 binding cleft are identical to
the corresponding residues of EphB2 (Koolpe et al.,
2005). However, there are important differences that
could explain the higher ligand selectivity of EphB4.
Several amino acid residues that make important con-
tacts with the ephrin G-H loop in the high-affinity dimer-
ization interface of EphB2 are not conserved in EphB4.
For example, Ser-194 of EphB2 is conserved in other
EphB receptors, but not in EphB4, where an alanine is
present at the corresponding position. Therefore,
EphB4 cannot form the polar interaction observed be-
tween the side chain of Ser-194 of EphB2 and the eph-
rin-B2 main chain oxygen of Glu-128. Furthermore, all
EphB receptors have an aromatic residue at the position
corresponding to Tyr-57 of EphB2. In EphB4, this posi-
tion is occupied by Leu (residue 48), which cannot
form a hydrogen bond with the main chain oxygen of
Pro-150 of ephrin-B2 or an aromatic-aromatic interac-
tion with Phe-113 of ephrin-B2, as observed for Tyr-57
of EphB2. Rather, Leu-48 would form only weak hydro-
phobic interactions with ephrin-B2. Leu-95 is present
in EphB4 at the corresponding Arg-103 position of
EphB2, resulting in the absence of another salt bridge
that is present in the dimerization interface of EphB2
with both ephrin-B2 and ephrin-A5 (Himanen et al.,
2001, 2004). The presence of a leucine is unique to
EphB4, because an arginine is conserved at this position
in all other Eph receptors across subclasses.
Some of the differences between EphB4 and the other
EphB receptors likely also explain the ability of the
TNYL-RAW peptide to selectively bind only to EphB4.
In particular, two non-conserved amino acids of
EphB4 make critical contacts with the high affinity-conferring RAW motif in the peptide. Leu-95 of EphB4
forms van der Waals interactions with both Phe-P3
and Trp-P15 of the peptide, aiding in the overall posi-
tioning of the peptide. The arginine present in the corre-
sponding position of all other Eph receptors (Arg-103 in
EphB2, see above) would result in steric clashes with
both Trp-P15 and Phe-P5 in the EphB4-TNYL-RAW
structure. Furthermore, Thr-147 of EphB4 forms hydro-
phobic interactions with several residues of the peptide,
and aids in the overall positioning of Phe-P5 from the
peptide. The phenylalanine present in the correspond-
ing position of other Eph receptors (Phe-155 in EphB2)
would instead result in a steric clash with Phe-P5 of
the peptide. The nonconserved Leu-48 of EphB4 also
contributes to peptide binding by forming a van der
Waals interaction with the tyrosine in the TNYL-RAW
peptide.
Additional differences in the lower-affinity tetramer in-
terface of EphB4 and other EphB receptors may further
contribute to the selectivity of EphB4 for ephrin-B2. For
example, EphB4 lacks several residues involved in inter-
actions that provide stability in the EphB2-ephrin-B2
tetrameric complex. Of particular interest is the absence
of the stacking interaction between Phe-128 (EphB2)
and Tyr-37 (ephrin-B2), due to the presence of an ala-
nine (Ala-120) at the equivalent position in EphB4. An al-
anine at this position should result in a substantial loss
of stability at the tetramer interface due not only to the
absence of the stacking interaction with the ephrin
aromatic residue, but also to the absence of interactions
with residues Ser-139, Gly-141, and Asn-142 of eph-
rin-B2. Interestingly, ephrin-B1 contains a serine at the
position corresponding to Tyr-37 in ephrin-B2, which
is also predicted to destabilize the tetramer interface
(Nikolov et al., 2005). In association with the missing
aromatic in EphB4 (Phe-128) at the tetramer interface,
formation of an EphB4-ephrin-B1 tetramer is highly un-
favorable, providing one explanation for the weak inter-
action between this receptor and ligand. In addition, the
presence in EphB4 of Thr-127 instead of Phe-135 of
EphB2 results in the absence of the hydrophobic inter-
action with Glu-134 of ephrin-B2, which is not replaced
by other interactions with the ephrin. Despite the weaker
contacts at the tetramer interface, we have found that
the EphB4 receptor can form a heterotetramer with the
ephrin-B2 ligand (data not shown).
An interesting feature of the Eph receptors is the flex-
ibility of their D-E and J-K loops, which line the high-af-
finity ephrin binding cleft (Himanen et al., 2004, 2001).
These loops are disordered in the apo structure of
EphB2, suggesting that a ligand is required to promote
their stability. EphB2 can accommodate ephrins of
both the A and B subclasses by shifting the position of
the J-K loop by more than 10 A˚. Furthermore, in the
structures of EphB2 in complex with ephrin-B2 or eph-
rin-A5, the J-K loop is positioned adjacent to the D-E
loop, forming weak hydrophobic interactions that likely
aid in the ordering of these loops. In the presence of
bound TNYL-RAW peptide, the J-K loop of EphB4 is
shifted by as much as 20 A˚ compared to the J-K loop
of apo EphB2, suggesting that this region can undergo
marked movements in order to accommodate a ligand.
Supporting the idea that a ligand stabilizes the confor-
mation of the Eph receptor ephrin binding domain,
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presence of the TNYL-RAW peptide, whereas the apo
form of the receptor did not crystallize.
The topology of the high-affinity binding cleft in com-
plex with the TNYL-RAW peptide can also accommo-
date the modeled ephrin-B2 G-H loop. Thus, despite
marked differences in the primary and secondary struc-
tures of the peptide and the ephrin G-H loop, the two li-
gands both similarly fit in the EphB4 binding cleft. It will
be interesting to model the many other EphB4-specific
peptides that were identified by phage display (Koolpe
et al., 2005) in order to gain information on the range of
residues that can be accommodated at each position,
as well as additional ligand structures that can be ac-
commodated by the ephrin binding cleft of EphB4.
Two of the peptides identified by phage display are
unrelated in sequence to TNYL-RAW, but share with
ephrin-B2 the sequence motif NxWxL (where x is any
amino acid). Several other peptides with different se-
quences also appear to target the ephrin binding cleft
of EphB4.
Although the precise roles of Eph receptor-ephrin bi-
directional signaling in angiogenesis are incompletely
understood, it is clear that the EphB4 receptor has a crit-
ical function because it is required for normal vascular
development in the embryo (Gerety et al., 1999). The
ability to modulate EphB4-ephrin-B2 binding will be
critical to dissect the roles of these molecules in tumor-
igenesis and angiogenesis. Furthermore, antagonizing
EphB4-ephrin-B2 binding will undoubtedly be of high
therapeutic value. High-affinity selective antagonists of
this interaction could be used to inhibit tumor angiogen-
esis (Martiny-Baron et al., 2004; Noren et al., 2004) and
pathological forms of angiogenesis, including inflam-
matory angiogenesis and the excessive retinal neovas-
cularization that plays an important role in retinopathy
of prematurity, macular degeneration, and diabetic ret-
inopathy (Yuan et al., 2004; Zamora et al., 2005). The
high-resolution structure of the ephrin binding domain
of EphB4 in complex with a highly selective and potent
peptide antagonist, which we report here, will allow
the design of novel compounds that recapitulate the
critical contacts of the peptide with EphB4 while having
good pharmacokinetic properties.
Experimental Procedures
Construct Design, Expression, and Purification of EphB4
Twelve sequential four amino-acid truncations in human EphB4
were designed based on EphB4-EphB2 sequence alignment in the
region C-terminal to the last b strand in the EphB2 structure. The re-
sulting fragments were cloned into the insect cell expression vector
pBAC6 (Novagen, San Diego, CA) under control of the heterologous
GP64 signal peptide and containing an N-terminal six histidine tag.
Constructs were sequence verified, and baculovirus was generated
with homologous recombination into Sapphire Baculovirus DNA
(Orbigen, San Diego, CA) following the manufacturers protocol. After
three rounds of viral amplification, a small-scale expression screen
was conducted for all constructs in both Sf9 and Hi5 insect cells.
Briefly, 5E10+6 cells were infected with baculovirus at an MOI of
2 in 38 mm tissue culture dishes; cells were harvested at 48 hr post-
infection, and supernatant containing secreted EphB4 was concen-
trated 10-fold and buffer exchanged into 50 mM Tris (pH 7.8),
400 mM NaCl, and 5 mM imidazole with an Amicon Ultra 5K concen-
trator (Millipore, Billerica, MA). The secreted protein was bound to
Ni-NTA magnetic beads (Qiagen, Valencia, CA), washed with
50 mM Tris (pH 7.8), 400 mM NaCl, and 20 mM Imidazole buffer,and eluted with 50 mM Tris (pH 7.8), 400 mM NaCl, and 250 mM
Imidazole. Based on analysis of immobilized metal affinity chroma-
tography (IMAC) elutes, the EphB4 (17–196) construct was identified
as the highest expressor atw6 mg/l in Hi5 insect cells. Large-scale
expression was conducted with Wave Bioreactors (Wave Biotech
LLC, Somerset, NJ) at an MOI of 2 for 48 hr in Hi5 insect cells. Media
containing secreted EphB4 were concentrated and buffer ex-
changed with a Hydrosart Crossflow filter (Sartorius, Edgewood,
NY). Following IMAC purification on ProBond resin (Invitrogen,
Carlsbad, CA) as described above, EphB4 was concentrated to
5 mg/ml and loaded on a Superdex 75 16/60 column (GE HealthCare,
Chicago, IL). A small amount of aggregated material was removed
by preparative size exclusion chromatography, while most of the
sample eluted in a single peak corresponding to an EphB4
(17–196) monomer. The complete removal of the GP64 secretion se-
quence and protein identity were confirmed by MALDI analysis.
Crystallization
Purified EphB4 was concentrated to 10 mg/ml in 25 mM Tris (pH 7.8),
150 mM NaCl, and 5 mM CaCl2 in the presence of a 3-fold molar ex-
cess of TNYL-RAW peptide (TNYLFSPNGPIARAW; Biopeptide, Inc.,
San Diego, CA). The EphB4 17–196 construct was crystallized by sit-
ting drop vapor diffusion at 20ºC against a reservoir of 2.2 M ammo-
nium sulfate and 200 mM NaCl, and cryoprotected in 25% glycerol.
Structure Determination
Crystals of the EphB4-TNYL complex grew in the P41212 space
group (a = 60.92, c = 151.93). A single crystal diffracted to 1.65 A˚ res-
olution at 100 K on beamline 5-1 at the Advanced Light Source (Ber-
keley, CA), and was integrated, reduced, and scaled with HKL2000
(Otwinowski and Minor, 1997). The structure was determined by mo-
lecular replacement with MolRep (CCP4i) (CCP4, 1994; Vagin and
Teplyakov, 1997) with the structure of apo EphB2 (PDB code:
1NUK [Himanen et al., 1998]) as a search model. The structure was
refined with CNS by torsion angle dynamics and the maximum likeli-
hood function target (Table 3), and manual model building per-
formed with the program O (Brunger et al., 1998; Jones et al.,
1991). Electron density for the TNYL-RAW peptide was clear after
Table 3. Crystallographic Statistics for the EphB4-TNYL-RAW
Complex
Resolution (A˚)a 40–1.65 (1.71–1.65)
Space group P41212
Unit cell dimensions (A˚) a = b = 60.97, c = 151.7











Bond length (A˚) 0.02








a Number in parentheses is for the highest shell.
b Rsym = SjI2 <I>j/SI, where I is the observed intensity and < I> is the
average intensity of multiple symmetry-related observations of that
reflection.
c Rcryst = SjFobsj 2 jFcalck/SjFobsj, where Fobs and Fcalc are the ob-
served and calculated structure factors. Rsym = SjI2 < I> j/SI, where
I is the observed intensity and <I> is the average intensity of multiple
symmetry-related observations of that reflection.
d Rfree = FobskFcalc/jFobsj for 10% of the data not used at any stage of
structural refinement.
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329the first round of refinement, with the positioning of the critical RAW
sequence clearly evident in the initial jFobsj2 jFcalcj maps (Figure 2).
The peptide was initially built as a polyalanine chain, while unbiased
electron density for the peptide from simulated annealing omit maps
was used to build the full peptide. Residues 17–196 from EphB4, and
14 of 15 residues from the TNYL-RAW peptide, could be readily
traced into electron density. The final structure exhibits good geom-
etry with no Ramachandran outliers. Figures were created with Py-
Mol, Molscript, Raster3D, Dino, Povray, and Ligplot (DeLano,
2002; Esnouf, 1997; Kraulis, 1991; Merritt and Murphy, 1994; Wallace
et al., 1995).
Isothermal Titration Calorimetry and ELISA Experiments
EphB4 and ephrin-B2 were either dialyzed or buffer exchanged into
50 mM Tris-Cl (pH 7.8 at 25ºC), 150 mM NaCl, and 1 mM CaCl2, prior
to use in calorimetry experiments. Peptides were dissolved into the
same buffer used for the dialysis of EphB4. The concentration of
EphB4, ephrin-B2, and the peptides was determined by measuring
the A280 and by the theoretical extinction coefficient (Gill and von
Hippel, 1989). ITC experiments were performed with a Microcal
MCS ITC at 25ºC. Following an initial injection of 2 ml, titrations
were performed by making 20 13 ml injections of peptide into
EphB4 in the sample cell to produce an approximate final 2:1 ratio
of injectant to sample in the cell. For most titrations, the sample
cell contained 15 mM EphB4 and the injection syringe contained
a 200 mM solution of the peptide. Titrations with ephrin-B2 contained
13 mM EphB4 in the sample cell and 290 mM ephrin-B2 in the syringe.
Prior to loading the sample cell, EphB4 was centrifuged at
18,000 3 g for 5 min at 4ºC to remove aggregates, and degassed
for 5 min at room temperature. Corrections for heats of dilution for
the peptides and ephrin-B2 were determined by performing titra-
tions of peptide or ephrin-B2 solutions into buffer. Dilution data
were fit to a line and subtracted from the corresponding titration
data. Titration data were analyzed with Origin ITC software version
5.0 (Microcal Software Inc.), and curves were fit to a single binding
site model (Wiseman et al., 1989). The low affinity of the TNYL pep-
tide and the limited availability of EphB4 (17–196) precluded accu-
rate determination of the Kd for this interaction by ITC. A lower limit
for the binding constant was determined by performing a titration
in which the sample cell contained 30 mM EphB4 and the injection
syringe contained a 1.45 mM solution of the peptide, producing a
final ratio of peptide to EphB4 of 10:1. The data were fit assuming
a stoichiometry of 1 and at least 60% saturation of binding at the final
peptide concentration (Turnbull and Daranas, 2003).
The ability of peptides to compete with the binding of mouse
ephrin-B2 alkaline phosphatase to immobilized mouse EphB4-Fc-
His (R&D Systems) was measured by ELISA as previously described
(Koolpe et al., 2005).
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